Literature DB >> 22382607

Diagnostics and new developments in the treatment of ocular allergies.

Osmo Kari1, K Matti Saari.   

Abstract

About 30% of people suffer from allergic symptoms, and 40% to 80% of them have eye symptoms. Atopic conjunctivitis is divided into seasonal allergic conjunctivitis and perennial allergic conjunctivitis. The treatment of seasonal allergic conjunctivitis is simple: antihistamines, anti-inflammatory agents, or cromoglycate. Perennial allergic conjunctivitis needs longer therapy with mast cell stabilizers and sometimes local steroids. Atopic keratoconjunctivitis requires long-term treatment of the lid eczema and keratoconjunctivitis. Vernal keratoconjunctivitis mainly affects children and young people. It commonly calms down after puberty. It demands intensive therapy, often for many years, to avoid serious complicating corneal ulcers. Giant papillary conjunctivitis is a foreign body reaction in contact lens users or patients with sutures following ocular surgery. Nonallergic eosinophilic conjunctivitis affects mostly middle-aged and older women with eosinophilic conjunctivitis and dry eye. Contact allergic blepharoconjunctivitis is often caused by cosmetics and eye medication. Work-related ocular allergies should be considered as a cause of resistant ocular symptoms in workplaces.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22382607     DOI: 10.1007/s11882-012-0252-9

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  40 in total

1.  Tacrolimus: a new topical immunomodulatory therapy for atopic dermatitis.

Authors:  S Reitamo
Journal:  J Allergy Clin Immunol       Date:  2001-03       Impact factor: 10.793

2.  Nasal and ocular effects in foundry workers using the hot box method.

Authors:  Håkan Löfstedt; Håkan Westberg; Anders I Seldén; Stig Rudblad; Ing-Liss Bryngelsson; Yen Ngo; Magnus Svartengren
Journal:  J Occup Environ Med       Date:  2011-01       Impact factor: 2.162

3.  Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009.

Authors:  G Walter Canonica; Jean Bousquet; Thomas Casale; Richard F Lockey; Carlos E Baena-Cagnani; Ruby Pawankar; Paul C Potter; Philippe J Bousquet; Linda S Cox; Stephen R Durham; Harold S Nelson; Giovanni Passalacqua; Dermot P Ryan; Jan L Brozek; Enrico Compalati; Ronald Dahl; Luis Delgado; Roy Gerth van Wijk; Richard G Gower; Dennis K Ledford; Nelson Rosario Filho; Erkka J Valovirta; Osman M Yusuf; Torsten Zuberbier; Wahiduzzaman Akhanda; Raul Castro Almarales; Ignacio Ansotegui; Floriano Bonifazi; Jan Ceuppens; Tomás Chivato; Darina Dimova; Diana Dumitrascu; Luigi Fontana; Constance H Katelaris; Ranbir Kaulsay; Piotr Kuna; Dèsirée Larenas-Linnemann; Manolis Manoussakis; Kristof Nekam; Carlos Nunes; Robyn O'Hehir; José M Olaguibel; Nerin Bahceciler Onder; Jung Won Park; Alfred Priftanji; Robert Puy; Luis Sarmiento; Glenis Scadding; Peter Schmid-Grendelmeier; Ester Seberova; Revaz Sepiashvili; Dirceu Solé; Alkis Togias; Carlo Tomino; Elina Toskala; Hugo Van Beever; Stefan Vieths
Journal:  Allergy       Date:  2009-12       Impact factor: 13.146

Review 4.  Allergic conjunctivitis: update on pathophysiology and prospects for future treatment.

Authors:  Santa Jeremy Ono; Mark B Abelson
Journal:  J Allergy Clin Immunol       Date:  2005-01       Impact factor: 10.793

Review 5.  Antihistamines in ocular allergy: are they all created equal?

Authors:  Mark B Abelson; James T McLaughlin; Paul J Gomes
Journal:  Curr Allergy Asthma Rep       Date:  2011-06       Impact factor: 4.806

Review 6.  Analysis of the mechanism for the development of allergic skin inflammation and the application for its treatment: mechanisms and management of itch in atopic dermatitis.

Authors:  Akihiko Ikoma
Journal:  J Pharmacol Sci       Date:  2009-07       Impact factor: 3.337

7.  Allergy in patients under fourteen years of age in Alergológica 2005.

Authors:  M D Ibáñez; J M Garde
Journal:  J Investig Allergol Clin Immunol       Date:  2009       Impact factor: 4.333

8.  Human eosinophils constitutively express multiple Th1, Th2, and immunoregulatory cytokines that are secreted rapidly and differentially.

Authors:  Lisa A Spencer; Craig T Szela; Sandra A C Perez; Casey L Kirchhoffer; Josiane S Neves; Amy L Radke; Peter F Weller
Journal:  J Leukoc Biol       Date:  2008-10-07       Impact factor: 4.962

9.  Allergic conjunctivitis, total and specific IgE in the tear fluid.

Authors:  O Kari; O P Salo; F Björkstén; A Backman
Journal:  Acta Ophthalmol (Copenh)       Date:  1985-02

10.  Complement activation in tear fluid during occupational mold challenge.

Authors:  S Peltonen; O Kari; H Jarva; H Mussalo-Rauhamaa; T Haahtela; S Meri
Journal:  Ocul Immunol Inflamm       Date:  2008 Sep-Oct       Impact factor: 3.070

View more
  4 in total

Review 1.  International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors.

Authors:  Pertti Panula; Paul L Chazot; Marlon Cowart; Ralf Gutzmer; Rob Leurs; Wai L S Liu; Holger Stark; Robin L Thurmond; Helmut L Haas
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

2.  In vitro effects of preserved and unpreserved anti-allergic drugs on human corneal epithelial cells.

Authors:  Ana Guzman-Aranguez; Patricia Calvo; Inés Ropero; Jesús Pintor
Journal:  J Ocul Pharmacol Ther       Date:  2014-08-06       Impact factor: 2.671

3.  Topical tacrolimus for the management of acute allergic conjunctivitis in a mouse model.

Authors:  Irina S Barequet; Eva Platner; Kobi Sade; Sara Etkin; Hana Ziv; Mordechai Rosner; Zohar Habot-Wilner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-04-05       Impact factor: 3.117

4.  Upregulation of the IL-33/ST2 pathway in dry eye.

Authors:  Shudan Wang; Hong Zhang
Journal:  Mol Vis       Date:  2019-10-06       Impact factor: 2.367

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.